Sat Kartar Life Ltd
Incorporated in June 2012, Sat Kartar Shopping Limited is an Ayurveda healthcare company that delivers natural wellness solutions for therapeutic and lifestyle products.[1]
- Market Cap ₹ 216 Cr.
- Current Price ₹ 137
- High / Low ₹ 220 / 110
- Stock P/E 13.7
- Book Value ₹ 42.9
- Dividend Yield 0.51 %
- ROCE 35.6 %
- ROE 26.5 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| 163 | 201 | |
| 149 | 176 | |
| Operating Profit | 14 | 25 |
| OPM % | 9% | 12% |
| 1 | 2 | |
| Interest | 1 | 1 |
| Depreciation | 1 | 3 |
| Profit before tax | 13 | 23 |
| Tax % | 25% | 26% |
| 10 | 17 | |
| EPS in Rs | 6.24 | 10.86 |
| Dividend Payout % | 11% | 6% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 23% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 62% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -18% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 26% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 16 | 16 |
| Reserves | 36 | 52 |
| 6 | 2 | |
| 7 | 15 | |
| Total Liabilities | 65 | 85 |
| 6 | 12 | |
| CWIP | 0 | 1 |
| Investments | 0 | 0 |
| 58 | 72 | |
| Total Assets | 65 | 85 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| -5 | 0 | |
| -0 | -9 | |
| 34 | -1 | |
| Net Cash Flow | 28 | -9 |
| Free Cash Flow | -10 | -7 |
| CFO/OP | -13% | 27% |
Ratios
Consolidated / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor Days | 13 | 26 |
| Inventory Days | 185 | 264 |
| Days Payable | 170 | 298 |
| Cash Conversion Cycle | 29 | -7 |
| Working Capital Days | 31 | 58 |
| ROCE % | 36% |
Insights
In beta| Mar 2025 | Mar 2026 | |
|---|---|---|
| Average Ticket Size INR ・Standalone data |
|
|
| Daily Unique Leads leads/day ・Standalone data |
||
| Hospital Bed Capacity beds ・Standalone data |
||
| Number of SKUs SKUs ・Standalone data |
||
| Pincodes Served pincodes ・Standalone data |
||
| Repeat Customer % % ・Standalone data |
||
| South India Revenue Share % ・Standalone data |
||
| Team Strength employees ・Standalone data |
||
Extracted by Screener AI
Documents
Announcements
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
- Submitted Regulation 74(5) certificate for quarter ended 30 September 2026.
-
Copy of Newspaper Publication
- Newspaper publication confirms EGM notice dispatch and remote e-voting for October 23, 2026 meeting.
-
Shareholders meeting
- EGM on 23 Oct 2026 to approve 5.5 lakh warrants, raising up to ₹9.46 crore.
-
Issue of Securities
- Board approved up to 5.5 lakh warrants worth ₹9.46 crore; EGM on October 23, 2026.
-
Outcome of Board Meeting
- Board approved 5.5 lakh convertible warrants at ₹172 each, raising up to ₹9.46 crore; EGM on October 23, 2026.
Concalls
-
May 2026Transcript PPT
-
May 2026PPT
-
Nov 2025Transcript
-
Nov 2025Transcript PPT REC
-
Oct 2025PPT
-
May 2025Transcript PPT REC
Business Model[1]
The company operates in the Ayurveda healthcare sector using a Direct-to-Consumer (D2C) model, combining Ayurvedic principles with modern research. It focuses on product innovation, branding, and marketing while outsourcing manufacturing to trusted partners, adopting an asset-light strategy.